TFF Pharmaceuticals (TFFP)
(Delayed Data from NSDQ)
$2.05 USD
-0.16 (-7.24%)
Updated May 29, 2024 03:59 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Brokerage Reports
TFF Pharmaceuticals, Inc. [TFFP]
Reports for Purchase
Showing records 121 - 140 ( 149 total )
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Robust Early Phase 1 Data - Systemic Tacrolimus Level Exceeds Expectation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Adding Cannabis Royalty Revenue to Model - Price Target to $23 from $18
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Results Describe a Novel High Potency Remdesivir Using TFF
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Highly Positive Phase 1 Voriconazole Results - Potential CAPA Opportunity
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20: Signs Niclosamide Deal, Well- Funded Pipeline, Raising PT to $18
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Successfully Completes Phase 1 Trial for Inhaled Dry Powder Voriconazole
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Shows That TFF Can Formulate Remdesivir as an Inhalable Dry Powder
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
TFF Vori Clears First Clinical Safety Hurdle, TFF Tac Begins Human Dosing
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Real Takeaways From a Virtual Roadshow - a Business Development Story
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20: Highly Active BizDev, Clinical Trials Progressing Despite COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
TFF Inventor Emphasizes Leveraging Repurposed Drugs to Hasten Discovery
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J